In Traditional Chinese Medicine (TCM) Ginkgo biloba L. leaves are used against chest pain, stroke, as lung diseases and cough [1] . Commercial refined extract of the drug can protect brain tissue against cerebral ischemia/reperfusion (I/R) injury [2] , an activity generally ascribed to the antioxidant activity of its flavonoids and proanthocyanidins.
Nevertheless, preliminary experiments identified 6-hydroxykynurenic acid (6-HKA) as a major contributor to this effect. It may thus serve as a potential active marker for drug quality analysis.
In contrast, genistein is a negative quality marker for this drug, as high contents of this compound in G. biloba leaves samples are in most cases caused by adulteration with Sophora flavescens Aiton, which is added to the extract by unlawful producers in order to boost its content in flavones, which serve as a major extract quality marker. Some publications even dispute the natural occurrence of genistein in G. biloba leaves altogether, thus claiming that its presence even in trace amounts would prove adulteration [3, 4] .
Genistein is synthesized in plants from the flavanone naringenin by a ring migration reaction catalyzed by the cytochrome P450 enzyme isoflavone synthase (IFS). Claims rejecting genistein as a natural constituent of G. biloba leaves and extracts are mainly based on the fact that IFS genes have not been detected in G. biloba neither during a search for isoflavone related genes in this species [5, 6] , nor during a large scale screening program of several plant genera for this specific gene [7] . However, although the presence of IFS in G. biloba has not been positively demonstrated, it is currently not possible to rule it out.
Alternatively, attempts have been made to explain its apparent presence in commercial extracts by postulating that G. biloba trees might be able to take up genistein from external sources via their roots if genistein containing fertilizers like mixed manure derived from soybeans or related Fabaceae crops are used [8] .
Due to the high international demand for the G. biloba leaves drug, G. biloba has been cultivated in many regions of China. However, many of the G. biloba cultivating companies use individual cultivation and harvesting techniques, which contribute to a large variety of G. biloba extracts on the Chinese market. The resulting inhomogeneity makes the identification of adulterated extracts even more difficult. The present study aims to determine the influence of harvesting time on the contents of genistein and 6-HKA in G. biloba leaves from different regions of China systematically and completely. It may thus contribute to the development of scientific standards for the cultivation and harvest of G. biloba leaves.
In the presented experiments, the fluctuations of the contents of 6-HKA and genistein in G. biloba leaves displayed some regional differences between the individual harvest areas but were as a whole relative consistent over the three years sampling period.
The minimum 6-HKA content was typically observed in August and July, with the highest contents occurring in May and October. Therefore, the collection of G. biloba leaves should be avoided in July and August in order to increase the content of desired 6-HKA. In contrast, the lowest genistein contents were typically observed in May and June, with the highest contents appearing in September and October. Thus, the collection of G. biloba leaves should be NPC Natural Product Communications 2017 Vol. 12 No. 8 1241 -1244 avoided in September and October in order to keep the content of undesired genistein as low as possible. All in all, the presented data hint to May and June as the most favorable harvest months for high quality G. biloba leaves raw drug material.
In conclusion, precise and reproducible HPLC methods for the quantification of both 6-HKA (Figures 1, 2 ) and genistein ( Figure  3 ) in G. biloba leaves were developed and validated (Tables 1-7) . As the application of these methods allowed for the identification of May and June as the most favorable harvest months (Table 8 -14, Figure 4 -8), these HPLC methods have already been proven of high relevance for safeguarding G. biloba leaves raw drug material quality. This is especially important as it facilitates minimal contents of undesired genistein in the resulting G. biloba leaves extract products.
This point is especially important as the presented results represent the first unambiguous proof that genistein is indeed a naturally occurring constituent of G. biloba leaves ( Figure 9 ) and by extension of the respective extract products -and therefore not prove of adulteration as claimed in previous publications [3, 4] . Whereas these previous publications exclusively concentrated on commercially purchased G. biloba leave extracts, the preparation of which the authors had no influence on, all extract samples examined in the paper at hand were prepared in house at Zhejiang CONBA from leave samples collected personally by the authors. In contrast to previous publications on the topic, we can therefore guaranty that no adulteration with Sophora spec. or any other genistein containing plant drug material did occur.
In addition, the presented data also refute the theory that G. biloba might be able to absorb genistein from soy beans or peanuts mixed manure used as fertilizer via the roots from the soil, as all fertilizers and agrochemicals used on the examined Zhejiang CONBA G. biloba plantations are purchased uniformly in accordance with current GMP standards and ISO9001:2000 regulations, demonstrating that no mixed manure from soy beans or peanuts or any related Fabaceae was used. All in all, the presented results demonstrate without reasonable doubt that in contrast to earlier theories genistein is indeed a naturally occurring constituent of G. biloba leaves and the respective extracts.
Experimental
Plant material: Tender leaves of 1-5 years old trees Ginkgo biloba L. were harvested from different plantations in China: Suizhou, Hubei; Mianyang, Sichuan; Bazhong, Sichuan; Lanxi, Zhejiang; Ningqiang, Shanxi. A basic unit of 500 acres was used for data collection. The sample collecting places consisted of different landforms including valleys, mountainsides, and hilltops, as well as both sunlit and shady places. All harvest sides were located on plantations (totaling 16.000 acres) owned and operated by Zhejiang CONBA Pharmaceutical (Hangzhou, China) in accordance with highest quality standards. No genistein containing fertilizers like mixed manure derived from soybeans or related Fabaceae crops were used during the production process.
6-HKA analysis:
Approximately 2 g of pulverized drug material was exactly weighted and extracted in 60 mL of MeOH (70% in H 2 O) at 60 °C on the heated ultrasonic bath for 45 min. Remaining plant material was removed by filtration through Whatman Filtration Paper. This liquid extract was concentrated to dryness under reduced pressure. The resulting dry extract was weighted, redissolved with the initial mobile phase (94% H 2 O, 5% C 2 H 3 N, 1% MeOH; pH 2.5) and subsequently washed into a 10 mL volumetric flask that was finally restocked to the 10 mL mark. Before injection, 1 mL of each extract was filtered through a Durapore 0.45 μm HV membrane syringe filter.
Analysis was performed on an Agilent HPLC 1260 system using a SB-C18 column (4.6 x 250 mm, 5 µm SN: USCL053720). The mobile phase consisted of phosphoric acid (pH 2.5) in water (solvent A), acetonitrile (solvent B) and methanol (solvent C), with the following gradient elution program: 0-14 min: 94% A, 5% B, 1% C; 16-25 min: 40% A, 50% B, 10% C; from 30 min to end: 94% A, 5% B, 1% C. The column was equilibrated with the initial mobile phase composition for 5 min before the each injection. The flow rate was set to 1.0 mL / min, the injection volume was 10 μl, and the column temperature was maintained at 25°C using a column oven. Detection was carried out using a PDA detector at λ max 350 nm.
Approximately 10.00 mg of 6-HKA standard substance was exactly weighted and dissolved in 50 mL of MeOH (70% in H 2 O). 1.0 mL of this stock solution was filled into a 10 mL volumetric flask that was finally restocked to the 10 mL mark with the initial mobile phase (94% H 2 O, 5% C 2 H 3 N, 1% MeOH; pH 2.5). Subsequently, 5 µL, 10 µL, 20 µL, 50 µL, and 100 µL of this 6-HKA standard solution were injected in order to generate a standard curve with a linear range from 0.005 to 0.1 mg/mL ( Figure 2 ).
All results suggest adequate sensitivity and reproducibility of the describe method. The % RSD value for inter-day variation was found to be 2.09 % in full compliance with the permissible limits (≤ 3%) for the precision of analytical methods developed ( Table 1) . The % RSD values for the stability tests were less than 2%, confirming the stability of 6-HKA during analysis ( Table 2 ). The percentage recovery for the six standard injections was in the range of 97.92 -100.7% with % RSD ≤ 1.27% (Table 3 ).
Genistein analysis:
Approximately 100 mg of pulverized drug material was exactly weighted and extracted in 20 mL of boiling MeOH (25% hydrochloric acid) under reflux for 80 min. Remaining plant material was removed by filtration through Whatman Filtration Paper. This liquid extract was concentrated to dryness under reduced pressure. The resulting dry extract was weighted, redissolved with the initial mobile phase and subsequently washed into a 50 mL volumetric flask that was finally restocked to the 50 mL mark. Before injection, 1 mL of each extract was filtered through a Durapore 0.45 μm HV membrane syringe filter.
Standard HPLC analysis was performed on an Agilent 1260 system using a SB-C18 column (4.6 x 250 mm, 5 μm SN: USCL053720). The mobile phase consisted of acetonitrile: methanol: formic acid (0.1 %) in water (2:4:4) (solvent A), methanol: formic acid (0.1%) in water (2:8) (solvent B), with the following gradient elution program: 0 min --> 25 min: 20% --> 100% A, 80% --> 0% B. The column was equilibrated with the initial mobile phase composition for 5 min before the each injection. The flow rate was set to 1.0 mL / min, the injection volume was 10 μl, and the column temperature was maintained at 25°C using a column oven. Detection was carried out using a PDA detector at λ max 350 nm.
LC-MS analysis was performed on a Waters UPLC system (Waters Corp., Milford, MA, USA), using a Agilent Zorbax SB-C18 column (4.6 x 250 mm, 5 μm SN: USCL053720). The injection volume was set at 10 μl, flow rate 1.0 mL min -1 . The mobile phase consisted of acetonitrile: methanol: formic acid (0.1 %) in water (2:4:4) (solvent A), methanol: formic acid (0.1 %) in water (2:8) (solvent B), with the following gradient elution program: 0 min--> 25 min: 20% --> 100% A, 80% --> 0% B. The additional UV detector was set at 260 nm.
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Mass Spectrometry: AB Triple TOF 5600 plus System (AB SCIEX, Framingham, USA). The optimal MS conditions: scan range m/z100-2000. Negative ion mode: source voltage was −4.5 kV and the source temperature was 550°C. The pressure of Gas 1 (Air) and Gas 2 (Air) were set to50 psi. The pressure of Curtain Gas (N 2 ) was set to 30 psi. Maximum allowed error was set to ±5 ppm. Declustering potential (DP), 100 V; collision energy (CE), 10 V. For MS/MS acquisition mode, the IDA-based auto-MS 2 was performed on the 8 most intense metabolite ions, the parameters were almost the same except that the collision energy (CE) was set at -40 ± 20 V, ion release delay (IRD) at 67, ion release width (IRW) at 25 in a cycle of full scan (1 s). The scan range of m/z of precursor ion and product ion were set as 100 − 2000 Da and 50 − 1500 Da, respectively. The exact mass calibration was performed automatically before each analysis employing the Automated Calibration Delivery System.
The standard curves for the area under the HPLC curve were linear within the range of 0.10 -5.30 ng of genistein ( Table 4 ). All results suggest adequate sensitivity and reproducibility of the describe method. The % RSD value for inter-day variation was found to be 1.18% in full compliance with the permissible limits (≤ 5%) for the precision of analytical methods developed ( Table 5 ). The % RSD values for the stability tests were less than 2.7%, confirming the stability of genistein during analysis ( Table 6 ). The percentage recovery for the six standard injections was in the range of 83.45 -91.02% with % RSD ≤ 3.32% (Table 7 ). 1244 Natural Product Communications Vol. 12 (8) 2017
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